Flame Biosciences, Inc.

Based in the US, Flame Biosciences, Inc. focuses on developing innovative biopharmaceutical solutions aimed at addressing unmet medical needs in oncology and other therapeutic areas. Flame Biosciences, Inc. is engaged in creating advanced therapies targeting various cancers.

Founded in 2017, its headquarters is located in the US. The company has successfully raised a total of USD 100. 00 mn through its funding activities, with the most recent financing round occurring on January 17, 2023, led by Rock Springs Capital. The founding team includes Harlan Weisman and Tim Opler, with Harlan Weisman serving as the CEO.

Flame Biosciences has completed three funding deals to date, with its latest financing aimed at further developing its product pipeline. The company specializes in providing innovative biopharmaceutical solutions tailored to meet the demands of its target markets. Its core product offerings include advanced therapies and clinical trial services designed to enhance treatment options for oncology patients. These solutions effectively address significant medical challenges, including improving patient outcomes in gastric, endometrial, and colorectal cancers.

The company serves a diverse client base that includes research institutions, healthcare providers, and pharmaceutical companies globally, ensuring its products have a broad reach across different sectors. The company's revenue model is primarily based on a combination of contractual agreements for the use of its therapies and partnerships with healthcare organizations. Clients typically engage in multi-year agreements for access to the company's products, which provide ongoing clinical support and updates. Additional revenue is generated through collaborations with research institutions, enhancing the company's financial stability while fostering long-term partnerships in the healthcare sector.

Flame Biosciences plans to expand its product line by launching new therapies targeting gastric, endometrial, and colorectal cancers, with initiatives expected to roll out by the end of 2024. The company aims to enter new geographic markets, including Europe and Asia, within the next two years. Recent funding of USD 100. 00 mn will be utilized to support these product developments and market expansions, particularly following its agreement to be acquired by Leap Therapeutics, which will enhance resources for advancing its clinical trials.